Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

The Lancet

Volumn 372, Issue 9633, 2008, Pages 89-90

  Sondak, Vernon K ^a   Flaherty, Lawrence E ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INTERFERON; PEGINTERFERON ALPHA2B;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; DISTANT METASTASIS FREE SURVIVAL; DRUG EFFICACY; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK BENEFIT ANALYSIS; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 46949091404     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61011-9     Document Type: Note

References (11)

1. Schucter L. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?. J Clin Oncol 22 (2004) 7-10
2. Kirkwood J., Tarhini A., Moschos S., and Panelli M. Adjuvant therapy with interferon α2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol 5 (2008) 2-3
3. Bukowski R., Ernstoff M., Gore M., et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 20 (2002) 3841-3849
4. Sondak V., and Daud A. Pharmacology of cancer biotherapeutics: interferons. In: DeVita Jr. V., Laurence T., and Rosenberg S. (Eds). Cancer: principles and practice of oncology. 8th edn. (2008), Lippincott Williams & Wilkins, Philadelphia 497-505
5. Eggermont A., Suciu S., Santinami M., et al., for the EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372 (2008) 117-126
6. Kilbridge K., Cole B., Kirkwood J., et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using Intergroup clinical trial data. J Clin Oncol 20 (2002) 1311-1318
7. Wheatley K., Ives N., Eggermont A., et al. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomized trials. J Clin Oncol 25 (2007) 478s (abstr).
8. Kirkwood J., Manola J., Ibrahim J., Sondak V., Ernstoff M., and Rao U. A pooled analysis of ECOG and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10 (2004) 1670-1677
9. Eggermont A., Suciu S., MacKie R., et al., for the EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366 (2005) 1189-1196
10. Tarhini A., Moschos S., Schlesselman J., et al. Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma. J Clin Oncol 26 (2008) 485s (abstr).
11. Gogas H., Ioannovich J., Dafni U., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354 (2006) 709-718